Cart
sales@molnova.com
SKLB 1028
CAS No. 1350544-93-2
SKLB 1028( —— )
Catalog No. M34711 CAS No. 1350544-93-2
SKLB 1028 (Ruserontinib) is a new type of oral multikinase inhibitor of EGFR, FLT3, and Abl. SKLB 1028 shows excellent activity in FLT3-driven AML models and considerable potency in CML models containing Abl mutants.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 78 | Get Quote |
|
| 5MG | 116 | Get Quote |
|
| 10MG | 187 | Get Quote |
|
| 25MG | 365 | Get Quote |
|
| 50MG | 542 | Get Quote |
|
| 100MG | 759 | Get Quote |
|
| 500MG | 1557 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameSKLB 1028
-
NoteResearch use only, not for human use.
-
Brief DescriptionSKLB 1028 (Ruserontinib) is a new type of oral multikinase inhibitor of EGFR, FLT3, and Abl. SKLB 1028 shows excellent activity in FLT3-driven AML models and considerable potency in CML models containing Abl mutants.
-
DescriptionRuserontinib (SKLB1028) is an orally active multikinase inhibitor of EGFR, FLT3 and Abl, with an IC50 value of 55 nM for human FLT3, and has antitumor activity.
-
In Vitro——
-
In VivoAnimal Model:MV4-11 and K562 xenograft NOD-SCID modelsDosage:5, 10, 20 mg/kg,70 mg/kg Administration:orally once daily, 18 days Result:Prevented tumor growth at a dose of 5 mg/kg, and caused rapid and complete tumor regression in both groups of mice at a dose of 10 or 20 mg/kg.Significantly inhibited the proliferation and induced apoptosis of MV4-11 and K562 cells at a dose of 70 mg/kg.
-
Synonyms——
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEGFR | FLT | Bcr-Abl
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1350544-93-2
-
Formula Weight443.55
-
Molecular FormulaC24H29N9
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 250 mg/mL (563.63 mM; Ultrasonic )
-
SMILESC(C)(C)N1C=2C(N=C1NC=3C=CC=NC3)=CN=C(NC4=CC=C(C=C4)N5CCN(C)CC5)N2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Z-X Cao, et al. SKLB1028, a novel oral multikinase inhibitor of EGFR, FLT3 and Abl, displays exceptional activity in models of FLT3-driven AML and considerable potency in models of CML harboring Abl mutants. Leukemia. 2012 Aug;26(8):1892-5.?
molnova catalog
related products
-
FRAX597
FRAX597 is an effective, ATP-competitive inhibitor of group I PAKs, and for PAK1(IC50=8 nM), PAK2(IC50=13 nM), and PAK3 (IC50=19 nM).
-
XL-647
XL-647 (Tesevatinib, EXEL-7647, KD-019) is a novel spectrum-selective kinase inhibitor that potently inhibits the EGFR, ErbB2, KDR and EphB4 with IC50 of 0.3, 16, 1.5 and 1.4 nM, respectively.
-
Poziotinib hydrochlo...
Poziotinib hydrochloride irreversibly inhibits EGFR (HER1 or ErbB1), including EGFR mutants, HER2, and HER4, thereby inhibiting the proliferation of tumor cells that overexpress these receptors.?It is an orally bioavailable, quinazoline-based pan epidermal growth factor receptor (EGFR or HER) inhibitor with potential antineoplastic activity.?
